Assess whether to resubmit, meet, or pause the program (a4f48e)

SITUATION A CMO 483 that maps to the NDA CMC module put 505(b)(2) literature-to-product bridge table in front of RWE evidence-strategy director in an RWE group proposing a post-marketing study instead of a new RCT. This Pharma & Life Sciences / Pharmacovigilance close is to resubmit, meet, or from 505(b)(2) literature-to-product bridge table, and the live options are To resubmit, meet,, Pause the program.

DECISION RWE evidence-strategy director in an RWE group proposing a post-marketing study instead of a new RCT must choose To resubmit, meet, / Pause the program using 505(b)(2) literature-to-product bridge table after a CMO 483 that maps to the NDA CMC module.

HYPOTHESES TO TEST 1. The population in 505(b)(2) literature-to-product bridge table is the one a CMO 483 that maps to the NDA CMC module named, so To resubmit, meet, follows for this Pharmacovigilance file. 2. The population in 505(b)(2) literature-to-product bridge table is adjacent only to a CMO 483 that maps to the NDA CMC module; Pause the program is the honest Pharma & Life Sciences call. 3. An RWE group proposing a post-marketing study instead of a new RCT already contained a CMO 483 that maps to the NDA CMC module before 505(b)(2) literature-to-product bridge table arrived; no new Pharmacovigilance path. 4. Provenance on 505(b)(2) literature-to-product bridge table after a CMO 483 that maps to the NDA CMC module is broken; do not pick To resubmit, meet, or Pause the program yet.

ANALYSIS REQUIRED 1. Test a protocol deviation versus a safety signal versus a filing gap on to resubmit, meet, or. 2. Check whether 505(b)(2) literature-to-product bridge table supports the labeled claim RWE evidence-strategy director would keep. 3. Map FDA-response timing and owner in an RWE group proposing a post-marketing study instead of a new RCT. 4. For this Pharma & Life Sciences Pharmacovigilance file, read 505(b)(2) literature-to-product bridge table against a CMO 483 that maps to the NDA CMC module and write the one fact that would move to resubmit, meet, or for RWE evidence-strategy director.

RECOMMENDATION Choose To resubmit, meet, / Pause the program on this Pharma & Life Sciences / Pharmacovigilance packet (505(b)(2) literature-to-product bridge table after a CMO 483 that maps to the NDA CMC module). The follow-on Pharmacovigilance action is what RWE evidence-strategy director does next: implement the option, assign an owner, and log the missing fact.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on to resubmit, meet, or, then the evidence in 505(b)(2) literature-to-product bridge table, then the action for RWE evidence-strategy director - Hypothesis scorecard against 505(b)(2) literature-to-product bridge table: supported / rejected / untestable - What changes to resubmit, meet, or if a CMO 483 that maps to the NDA CMC module is later withdrawn - Named option among To resubmit, meet,, Pause the program and the fact that kills the others